Form 8-K - Current report:
SEC Accession No. 0001213900-24-052439
Filing Date
2024-06-13
Accepted
2024-06-13 16:05:33
Documents
14
Period of Report
2024-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207772-8k_inmune.htm   iXBRL 8-K 25130
2 INCENTIVE STOCK OPTION AGREEMENT BETWEEN INMUNE BIO INC. AND DR. TESI, DATED JUN ea020777201ex10-1_inmune.htm EX-10.1 35270
  Complete submission text file 0001213900-24-052439.txt   244601

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20240610.xsd EX-101.SCH 3018
4 XBRL LABEL FILE inmb-20240610_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20240610_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0207772-8k_inmune_htm.xml XML 3797
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241041230
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)